MELANOMA BRIDGE
December 3rd - December 5th, 2020
VIRTUAL MEETING
December 3rd 2020
MELANOMA BRIDGE OPENING SESSION**
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
| 09.20 PM | Anti-cancer responses to the spectrum of “Cancer Antigens” and immune contraction**, Bernard A. Fox |
| 09.40 PM | The immune contexture for survival and immunotherapy response**, Jerome Galon |
December 4th 2020
| 12.30 PM | Introduction and objectives, Paolo A. Ascierto |
Session - Melanoma as a model system
Chairpersons: Giuseppe Masucci, Magdalena Thurin
| 12.40 PM | Targeting the microbiota in melanoma anti-PD1 therapy, Giorgio Trinchieri |
| 12.55 PM | Prediction of response to check point inhibition: is there a simple but not simplistic way? Iman Osman |
| 01.10 PM | Immunotherapy-induced anti-cancer responses, Bernard A. Fox |
| 01.25 PM | The role of CD39 in melanoma, Michele Teng |
| 01.40 PM | Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin |
| 01.55 PM | Break ** |
| 02.25 PM | b Adrenergic Receptors: "A non-canonical Immune Checkpoint?", Marc Ernstoff |
| 02.40 PM | Escape mechanisms in melanoma, Soldano Ferrone |
| 02.55 PM | Electrochemotherapy in metastatic melanoma, Corrado Caracò |
| 03.10 PM | Uveal Melanoma, Richard D. Carvajal |
| 03.25 PM | Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin |
| 03.40 PM | SYMPOSIUM Target therapy in Melanoma |
| The role of target therapies in the treatment of Melanoma Braf positive between present and future, Paul Nathan, Paolo A. Ascierto |
| 04.30 PM | Break ** |
SESSION 3 MECHANISMS OF RESISTANCE AND DRIVERS OF RESPONSE
Chairpersons: Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri
| 04.45 PM | SYMPOSIUM Adjuvant Therapy |
| Adjuvant therapy in melanoma: maximizing the chances for a cure Olivier Michielin, Paolo A. Ascierto |
| 05.35 PM | Translational research in the metastatic melanoma, Reinhard Dummer |
| 05.50 PM | Intrinsic tumor genomic and metabolic factors , Patrick Hwu |
| 06.05 PM | Achieving durable MAPK Suppression and Invigorating Anti-melanoma T Cell Immunity, Roger Lo |
| 04.30 PM | Break ** |
| 06.35 PM | Tumor mutation burden and liquid biopsies, Claus Garbe |
| 06.50 PM | Mechanisms of resistance to cancer immunotherapy, Thomas F. Gajewski |
| 07.05 PM | T-cell intrinsic mechanisms of resistance to PD1 checkpoint blockade, Michelle Krogsgaard |
| 07.20 PM | Targeting dendritic cells to enhance the effectiveness of PD1 blockade against cold tumors, Pawel Kalinski |
| 07.35 PM | Discussion on Mechanisms of resistance and drivers of response, Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri |
December 5th 2020
SESSION EMERGENT STRATEGIES
Chairpersons: Alexander M. Eggermont, Alessandro Testori
| 12.30 AM | SYMPOSIUM IO and adjuvant therapy in melanoma |
| Adjuvant immunotherapy in melanoma: current practice and future directions, Georgina V. Long, Paolo A. Ascierto |
| 01.20 PM | Neoadjuvant Immunotherapy - less is more , Christian Blank |
| 01.35 PM | What are new ways to think about immunotherapy combinations for melanoma? Michael A. Postow |
| 01.50 PM | Considering QUAD therapy to address unmet needs in high risk BRAF mutant melanoma, Jason Luke |
| 02.05 PM | Break ** |
| 02.20 PM | Development of novel antibodies targeting regulatory T cells in cancer, Sergio Quezada |
| 02.35 PM | Oncolytic virus combo with CKI- Ipi talimogene laherparepvec and talimogene laherparepvec+Pembrolizumab, Igor Puzanov |
| 02.50 PM | Exploring the potential of dendritic cell therapy for the treatment of advanced melanoma, from moDC to myDC, Bart Neyns |
| 03.05 PM | Discussion on Emergent strategies, Alexander M. Eggermont, Alessandro Testori |
| 03.35 PM | Break ** |
SESSION GREAT DEBATE
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
| 03.50 PM | Is innate immunity important: yes or no? Jeffrey S. Weber, Alexander M. Eggermont |
| 04.20 PM | Discussion on "Is innate immunity important: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 04.30 PM | Does AJCC classification an emprovement for better staging: yes or no? Jeffrey E. Gershenwald, Jean-Jacques Grob |
| 05.00 PM | Discussion on "Does AJCC classification an emprovement for better staging: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 05.10 PM | Break ** |
| 05.25 PM | Is the sentinel node biopsy useful for staging patient: yes or no? Vernon K. Sondak, Jean-Jacques Grob |
| 05.55 PM | Discussion on "Is the sentinel node biopsy useful for staging patient: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 06.05 PM | Triplette combination (target therapy plus IO) VS combo IO Jeffrey A. Sosman, Michael B. Atkins |
| 06.35 PM | Discussion on "Triplette combination (target therapy plus IO) VS combo IO" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 06.45 PM | Break ** |
| 07.00 PM | Neoadjuvant or adjuvant therapy: which is better? Hussein A. Tawbi, Omid Hamid |
| 07.30 PM | Discussion on "Neoadjuvant or adjuvant therapy: which is better?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 07.40 PM | What we will do on Monday? Sanjiv S. Agarwala |
| 07.55 PM | Conclusions Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
For information please contact info@melanomabridge.org
